ALK and non-small cell lung carcinoma: In May 2020, based on the data from CHECKMATE‐9LA (NCT03215706), nivolumab plus ipilimumab and two cycles of chemotherapy as first‐line treatment for metastatic NSCLC patients without EGFR or ALK mutations were approved by the U.S. FDA.296